The expression of exo-AnxA2 levels in serum samples of different breast cancer subtypes with tumor grades clearly suggests that the progressive increase of exo-AnxA2 levels seen in serum samples of breast cancer patients (Fig. 3a) is specifically associated with TNBC subtypes of breast cancer (Fig. 5b). Here, ANXA2 is linked to breast carcinoma.